Life Insurance Corporation of India (LIC) has trimmed its stake in Zydus Lifesciences, offloading 20.24 million shares. The institutional investor reduced its holding from 5.21% to 3.18% between August 2025 and November 2026, marking a significant shift in the company's major shareholding structure.
LIC Trims Stake in Zydus Lifesciences to 3.18%
Shares sold: 20,242,068 | New shareholding: 3.184%
Reader Takeaway: Major institutional divestment suggests portfolio rebalancing; monitor for further signals from other long-term institutional holders.
What just happened
Life Insurance Corporation of India (LIC) has officially reduced its equity stake in Zydus Lifesciences Ltd. According to the latest BSE filing, the insurance giant sold 20,242,068 shares in the open market. These transactions occurred between August 28, 2025, and November 5, 2026.
Why this matters
LIC’s stake reduction brings its total holding down from 5.213% to 3.184%. This divestment involves a total of 2.029% of the company’s equity capital. Under SEBI regulations, disclosures are mandatory when an entity’s shareholding changes by more than 2% for those previously holding over 5% of a firm. The company’s total voting capital remained stable at 997,503,832 shares throughout this period.
What to track next
Investors should monitor the upcoming shareholding pattern disclosures to determine if this divestment represents a broader shift in institutional sentiment toward Zydus Lifesciences or a routine rebalancing of LIC’s portfolio. Further changes in the top 10 shareholder list will provide clarity on whether other institutional investors are following suit or absorbing the supply.